<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453619</url>
  </required_header>
  <id_info>
    <org_study_id>APL2-201</org_study_id>
    <nct_id>NCT03453619</nct_id>
  </id_info>
  <brief_title>Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2&#xD;
      subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients&#xD;
      with glomerulopathies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">April 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proteinuria reduction by 50%, calculated by the change in uPCR from baseline to Week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Disease Specific Biomarkers</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete clinical remission defined as normalization of proteinuria as defined by &lt;200 mg/g uPCR at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stabilization or improvement in estimated Glomerular Filtration Rate (eGFR) from baseline to Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>IgA Nephropathy</condition>
  <condition>Lupus Nephritis</condition>
  <condition>Membranous Nephropathy</condition>
  <condition>C3 Glomerulonephritis</condition>
  <condition>Dense Deposit Disease</condition>
  <arm_group>
    <arm_group_label>APL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label, Study Drug, APL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-2</intervention_name>
    <description>APL-2 administered as a daily subcutaneous infusion for 48 weeks</description>
    <arm_group_label>APL-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of at least 18 years of age at screening (16 years of age for C3G), able to&#xD;
             provide written informed consent, and able to understand and comply with all scheduled&#xD;
             procedures and other requirements of the study by the opinion of Principal&#xD;
             Investigator (PI)&#xD;
&#xD;
          -  Patients must have a diagnosis of IgAN, LN, Primary MN, or C3G confirmed by renal&#xD;
             biopsy and required measurements performed prior to study participation&#xD;
&#xD;
               -  IgAN: Prior biopsy results for C3 and C4d staining should be made available&#xD;
&#xD;
               -  LN: Diagnostic biopsy showing proliferative focal, diffuse, or membranous lesions&#xD;
                  (Class III, IV or V, respectively) by renal biopsy. Subject should have either a&#xD;
                  biopsy in the last 6 months, or evidence of disease activity (nephritic changes&#xD;
                  on urinalysis or nephrotic changes)&#xD;
&#xD;
               -  Primary MN: PLA2R positive titer plus nephrotic range proteinuria (defined as&#xD;
                  uPCR &gt;2350 mg/g)&#xD;
&#xD;
               -  C3G plus one of the following: Low serum C3 level or historical renal biopsy&#xD;
                  within the last 3 years&#xD;
&#xD;
          -  Have proteinuria &gt;750 mg/g (calculated by uPCR on 24 hour urine collection) collected&#xD;
             during the first screening visit (Visit 3a).&#xD;
&#xD;
          -  eGFRâ‰¥30mL/min/1.73 m2 calculated by CKD-EPI creatinine equation at screening visit 3a&#xD;
             and currently not on dialysis&#xD;
&#xD;
          -  Must have stable or worsening renal disease, on stable and optimized treatment, in the&#xD;
             opinion of the PI, for at least 2 months prior to the first dose of APL-2 (Visit 4);&#xD;
             treatments may include, but are not limited to, immunosuppressive agents,&#xD;
             anti-hypertensives and/or anti-proteinurics.&#xD;
&#xD;
          -  Willing to receive vaccinations against Neisseria meningitidis at least 2 weeks prior&#xD;
             to dosing on Day 1 with a booster on Day 56 (for both vaccinations) and Pneumococcal&#xD;
             and Hib vaccines at least 2 weeks prior to dosing on Day 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute neutrophil count &lt;1000 cells/mm3 at screening Visits 3a and 3b&#xD;
&#xD;
          -  ALT or AST &gt;3.0 x the upper limit of normal at screening Visits 3a and 3b&#xD;
&#xD;
          -  Previous treatment with APL-2&#xD;
&#xD;
          -  History of solid organ transplant&#xD;
&#xD;
          -  Diagnosis of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C&#xD;
             infection, or positive serology at screening Visits 3a and 3b (previous HBV or HCV&#xD;
             diagnosis cleared by treatment is allowed)&#xD;
&#xD;
          -  Renal disease secondary to another condition (e.g. infection, malignancy, monoclonal&#xD;
             gammopathy, or a medication)&#xD;
&#xD;
          -  Presence or suspicion of active bacterial or viral infection or severe recurrent&#xD;
             bacterial infections&#xD;
&#xD;
          -  Participation in any other investigational drug trial or exposure to other&#xD;
             investigational agent, device, or procedure within 30 days prior to screening period&#xD;
&#xD;
          -  Unwillingness to receive or intolerant of SC infusions of study medication or known&#xD;
             allergy to ingredients in APL-2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthONE Physician Care, Rocky Mountain Hospital for Children</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Nephrology Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research LLC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Nephrology Associates</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Nephrology Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Health</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Nephrology Associates</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milwaukee Nephrologists</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <disposition_first_submitted>August 27, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 2, 2020</disposition_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

